In Part 1, we discussed why patent
translation for innovative medicines should be planned earlier in the
globalization process, along with some of the language risks that commonly
arise.
But planning early does not mean completing
every translation task in advance. What companies really need is a language
management framework that can be reused throughout the patent lifecycle:
establishing the foundation when preparing the PCT application, maintaining
multilingual consistency during the national phase, and extending that
framework to Office Action responses and other subsequent filings.
1. From PCT Application to National Phase: How Should
Innovative Pharmaceutical Companies Plan Their Patent Translation Strategy?
PCT Application Stage: Build a Reusable Language
Foundation First
The PCT application stage is an important
point for planning multilingual patent language, although some preparation
can—and ideally should—begin even earlier.
Before entering the national phase in
multiple jurisdictions, companies can establish a foundational terminology
framework covering the core active ingredient, target, indication, formulation,
route of administration, and other key technical features. The company and its
patent team should confirm the technical meaning and patent strategy, while the
language services team can turn the approved terminology and expression rules
into reusable language assets.
The goal here is not simply to create a
static glossary. It is to establish a set of language rules that can be applied
consistently throughout the later stages of the project.
For example, should the same active
ingredient always use the same core translation in the specification, claims,
and subsequent Office Action responses? Should similar technical features
follow standardized wording? When new terminology appears, who approves it, and
how is the terminology database updated? These basic rules should be
established early.
For innovative pharmaceutical companies
planning to enter multiple jurisdictions, it is also useful to establish
language mappings across the patent family at this stage, identifying the
languages, document types, and core terminology involved in each market. This
creates a stronger foundation for the national phase.
National Phase: Move from Multilingual Translation to
Consistency Management
Once an application enters the national
phase, the focus of language management shifts from translating individual
documents to coordinating terminology and content across documents and
languages.
The same technology may enter very
different linguistic environments and patent procedures in markets such as the
United States, Europe, and Japan. At this point, the question is not simply
whether the translation reads naturally in the target language. Companies also
need to consider:
- Whether core terminology remains aligned with the earlier PCT text;
- Whether key technical features in the claims remain consistent;
- Whether wording differs between the specification and the claims;
- Whether terminology across patent family members can be traced back to an agreed source;
- Whether amended text continues to follow previously approved language conventions.
High-quality translation at the national
phase is therefore better understood as a controlled multilingual language
conversion and consistency management process, rather than a series of
independent translation projects restarted from the original Chinese document.
2. How Can Regulatory Submissions and Patent Documents
Maintain Terminology Consistency?
Innovative pharmaceutical companies
typically work with two major international language systems at the same time:
one supporting regulatory submissions and communications, and the other
supporting patent filing and IP protection.
These two systems serve different purposes,
and their wording should not be expected to be completely identical. What needs
to remain consistent is the underlying technical meaning and the core
terminology.
For example, the same active ingredient,
target, disease name, or mechanism of action may be expressed in different
sentence structures in regulatory submissions and patent documents to suit
their respective contexts. However, the core names and conceptual relationships
should remain stable.
A more practical approach is therefore to
keep the underlying terminology aligned while allowing the wording to vary by
context.
This helps prevent obvious terminology
conflicts between regulatory submissions and patent documents while preserving
the professional conventions appropriate to each type of document.
From a long-term project management
perspective, this coordination can be particularly valuable. Companies often
need to cross-reference technical documents, regulatory materials, and
intellectual property records when reviewing patent information, comparing
product materials, or coordinating internally. The more consistent the
underlying language assets are, the easier it becomes to verify information and
trace it back to the source.
3. Office Action Responses: How Can Companies Continue
Working Within an Established Patent Language Framework?
Once an application enters examination in
the national phase, Office Action responses often involve claim amendments,
explanations of technical features, and newly introduced wording. At this
point, language services need to shift from simply completing a translation to
managing changes in the existing language framework.
In practice, three areas deserve particular
attention.
3.1 Distinguish Existing Content from New Content
The first step is to identify which parts
of the Office Action response already appear in the original application or
previous translations, and which parts have been newly added, amended, or
rephrased.
For existing content, previously approved
terminology and wording should be retained wherever possible. For new content,
terminology should be reviewed against the project terminology database and the
surrounding context to avoid introducing a new translation simply because of a
localized amendment.
3.2 Focus Review Efforts on Amended Claims
An Office Action response does not mean
that every part of the document requires the same level of review.
Claims that have been amended,
supplemented, or substantially reworded, as well as passages involving core
technical features, should receive closer linguistic review. The goal is to
ensure that the amended wording remains aligned with the specification,
previously approved translations, and the underlying technical content.
3.3 Turn Each Response into a New Project Language Asset
Every Office Action response can introduce
new terminology, new phrasing, and new records of approved amendments.
After each response is completed, the
terminology database, translation memories, and relevant language mappings
should therefore be updated promptly. When the next Office Action or a related
patent family project begins, previously approved content can then be reused
directly.
In this way, an Office Action response
becomes more than a one-off document. It becomes part of the ongoing
accumulation of patent language assets.
4. Can AI Be Used for Innovative Pharmaceutical Patent
Translation?
Yes—but for innovative pharmaceutical
patent projects, AI is generally more effective as part of a risk-based,
AI-assisted and human-led workflow than as an uncontrolled end-to-end machine
translation tool.
AI can handle tasks that are relatively
well defined and repetitive, such as:
- Terminology retrieval and candidate matching;
- Translation memory retrieval;
- Draft generation for highly repetitive content;
- Cross-document terminology consistency checks;
- Basic quality checks for formatting, tags, and other structural elements.
However, high-risk content—including core
claims, key technical limitations, numerical ranges, newly added or amended
content, and Office Action responses—still requires focused review by qualified
professionals.
The real value of an AI-assisted human
workflow does not come from simply changing the process to “AI translation +
human proofreading.” The more effective approach is to determine where AI
should be used based on text risk, technical complexity, and the intended use
of the content.
For lower-risk, repetitive content, AI can
improve processing efficiency. For high-risk and legally significant content,
professional review should remain the priority.
This risk-based model allows companies to
take advantage of AI when handling large-scale multilingual projects while
directing limited expert review resources toward the content that requires
genuine professional judgment.
5. A Typical Project Scenario: How Can Multilingual Patent
Rework Be Reduced?
Consider an innovative pharmaceutical
company planning to pursue the US, European, and Japanese markets at the same
time.
If the company only completes the English
text at the PCT stage and waits until the national phase to launch separate
projects for each language, it may repeatedly need to confirm how the same
active ingredient, technical feature, or claim language corresponds across
different documents and jurisdictions.
A more effective project model is to
establish the core terminology database and patent-family language mapping at
an early stage, while treating core claims and key technical features as
priority review items. Once the application enters the national phase, new
language projects can build on the existing language assets. At the Office
Action stage, earlier application and translation records can be referenced
rather than reconfirming terminology that has already been approved.
The value of this approach may not
necessarily be obvious in the form of a dramatically faster single translation
project. Its real benefit becomes clearer as the patent family expands and the
amount of repeated confirmation work decreases.
The value of establishing language rules
early often becomes increasingly visible across multiple countries, documents,
and examination cycles.
6. How Can Companies Build a Language Management Framework
for Innovative Pharmaceutical Patents?
For companies pursuing long-term
international patent portfolios, this approach can be organized into four core
components.
6.1 Front-Load Terminology Management
Build a controlled terminology framework
around core drug-related concepts, technical features, and disease areas, with
clear rules for terminology approval, updates, and reuse.
A terminology database should not be
treated as a one-time project file. It should be maintained continuously as the
patent family expands and R&D progresses.
6.2 Manage Consistency Across the Patent Family
Establish clear relationships among the PCT
text, national-phase documents, translations of patent family members, and
subsequent amendments.
The objective is not to force
sentence-by-sentence alignment across languages, but to keep core terminology,
technical references, and key expressions stable and traceable.
6.3 Apply Risk-Based Review
Set different review levels according to
document type and text risk.
Core claims, key technical features, and
Office Action responses require a higher level of professional review.
Repetitive content with relatively manageable risks can be handled through more
efficient workflows.
6.4 Use Controlled AI Assistance and Quality Checks
Apply AI to areas suited to automation,
such as terminology retrieval, translation memory, draft generation, and
consistency checks. At the same time, use professional review and quality
control mechanisms to limit the degree of automation applied to high-risk
content.
Once these four components are connected,
companies are no longer managing a collection of isolated translations. They
are building language assets that can be reused across projects, languages, and
stages of the patent lifecycle.
7. From One-Time Translation Projects to Reusable Patent
Language Assets
For innovative pharmaceutical companies,
the real language challenge is not any single document. It is maintaining
consistency across the entire patent lifecycle—from the PCT application and
national phase to Office Action responses and subsequent patent-related work.
The earlier a company establishes
terminology controls, patent-family language planning, and risk-based review
mechanisms, the easier it becomes to build new multilingual projects on top of
existing language assets.
Glodom combines professional translation,
terminology management, consistency control, and AI-assisted capabilities to
support projects in the life sciences and intellectual property sectors. Our
goal is to help companies move beyond one-off document delivery and build
patent language resources that can be reused over time.
For innovative pharmaceutical companies
pursuing global patent protection, bringing language management into the patent
workflow early can make it easier to manage the complexity that comes
later—across different jurisdictions, document types, and stages of
examination.
About Glodom
Shenzhen Glodom Smart Technology Co., Ltd. (Glodom) is an innovative language technology solutions provider with extensive experience in patent-related projects and long-standing partnerships with Fortune Global 500 companies and professional organizations.
Glodom has more than 300 full-time professionals and a global network of more than 10,000 native translators across 40+ countries, supporting more than 200 languages. We provide efficient and accurate language support for patent applications, patent translation, patent invalidation, patent litigation, and related technical documentation.
We combine professional expertise with
delivery efficiency, supported by mature terminology management, rigorous
quality control processes, and extensive multilingual project experience.
Through these capabilities, we help companies address language challenges in
international patent work and strengthen compliance and competitiveness as they
expand their global IP portfolios.
